A Phase 3 interventional study of Apremilast 20mg and Apremilast 30mg in Psoriatic Arthritis, sponsored by Amgen. Completed at 98 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-05-06.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing apremilast in Arthritis, Psoriatic — 3 open to participants now, 3 under way, 1 of them phase 3. apremilast · Arthritis, Psoriatic.
Among the 17 studies testing apremilast in Arthritis, Psoriatic, this one is the 4th largest by enrollment, is one of 4 that started in 2010, is one of 8 in phase 3, and was the 3rd registered.
601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.
Browse Arthritis, Psoriatic studies →3 of the 17 studies testing apremilast in Arthritis, Psoriatic are open now, in 2 countries. Recruiting first, the newest first:
University of Erlangen-Nürnberg Medical School · Sites in Germany
Ages 18–75
Tanta University · Sites in Egypt
Ages 18–70
Amgen
Ages 18–60 · Healthy volunteers
By country, each count listing its studies:
apremilast: first FDA approval 2014 (OTEZLA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 4 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 488 is above the median of 145 across 337 interventional studies indexed under Arthritis, Psoriatic.
Median enrollment 219 across the 17 interventional studies. Of the 11 that completed or were terminated, 10 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 17 have an industry lead sponsor. The 7 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
21 studies in Arthritis, Psoriatic by Amgen: 1 open now, 1 under way, none of them phase 3. Of 20 finished, 13 (65%) have results posted.
Among the 21 studies in Arthritis, Psoriatic by Amgen, this one is the 5th largest by enrollment of the 15 interventional ones that give a count, is one of 4 that started in 2010, is one of 9 in phase 3, and was the 5th registered.
Amgen’s Arthritis, Psoriatic studies by the year they started, since 2000.
2 of the studies testing apremilast in Arthritis, Psoriatic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07398651Tanta UniversityApremilast and Adalimumab in Psoriatic Arthritis Patients | 2026-12-30 |
| NCT07908641AmgenComparing the Extent to Which Apremilast is Made Available in the Body After Administration as an Extended-release or Immediate-release Formulation | 2027-01-10 |
Add all 2 to your calendar (.ics) → With an account.
Among the 17 studies testing apremilast in Arthritis, Psoriatic, from their registry updates:
Among Amgen’s 21 in Arthritis, Psoriatic:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether apremilast is safe and effective in the treatment of patients with psoriatic arthritis.
Apremilast is proposed to improve signs and symptoms of psoriatic arthritis (tender and swollen joints, pain, physical function) in treated patients.
Psoriatic arthritis (PsA) is an inflammatory arthritis that occurs in 6-39% of psoriasis patients. The immunopathogenesis of PsA, which mirrors but is not identical to that seen in psoriatic plaques, reflects a complex interaction among resident dendritic, fibroblastic and endothelial cells, and inflammatory cells attracted to the synovium by cytokines and chemokines. Apremilast (CC-10004) is a novel oral agent that modulates multiple inflammatory pathways through targeted phosphodiesterase type 4 (PDE4) enzyme inhibition. Therefore, apremilast has the potential to be effective in the treatment of PsA.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
20 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 20 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase
Drug: Apremilast 20mg
30 mg Apremilast tablets administered twice a day for 24 weeks during the placebo-controlled phase followed by 30 mg Apremilast tablets administered twice a day for up to 4.5 years in the active treatment / long-term safety phase orally twice daily
Drug: Apremilast 30mg
Placebo + 20 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 20 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase. Subjects who do not have at least 20% improvement in their swollen and tender joint counts at Week 16 will escape to 20 mg Apremilast twice daily at Week 16
Drug: Placebo + 20 mg Apremilast
Placebo + 30 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 30 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase. Subjects who do not have at least 20% improvement in their swollen and tender joint counts at Week 16 will escape to 30 mg Apremilast twice daily at Week 16.
Drug: Placebo + 30 mg Apremilast
Apremilast 20 mg twice daily, orally
Also known as: CC-10004
Apremilast 30 mg twice daily, orally
Also known as: CC-10004
Placebo + 20 mg Apremilast
Also known as: Placebo, CC-10004
Placebo + 30 mg Apremilast
Also known as: Placebo, CC-10004
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16
Percentage of participants with an ACR20 response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 20% improvement in 78 tender joint count; • ≥ 20% improvement in 76 swollen joint count; and • ≥ 20% improvement in at least 3 of the 5 following parameters: ◦Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦C-Reactive Protein.
Time frame: Baseline and Week 16
Change From Baseline in Health Assessment Questionnaire- Disability Index (HAQ-DI) at Week 16
The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire consisting of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task are summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement in functional ability.
Time frame: Baseline and Week 16
Percentage of Participants With an ACR 20 Response at Week 24
Percentage of participants with an American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 20% improvement in 78 tender joint count; • ≥ 20% improvement in 76 swollen joint count; and • ≥ 20% improvement in at least 3 of the 5 following parameters: ◦Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦C-Reactive Protein.
Time frame: Baseline and Week 24
Change From Baseline in Health Assessment Questionnaire- Disability Index (HAQ-DI) at Week 24
The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire consisting of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task are summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement in functional ability.
Time frame: Baseline and Week 24
Change From Baseline in 36-item Short Form Health Survey (SF-36) Physical Functioning Domain at Week 16
The Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). Norm-based scores were used in analyses, calibrated so that 50 is the average score and the standard deviation equals 10. Higher scores indicate a higher level of functioning. The physical functioning domain assesses limitations in physical activities because of health problems. A positive change from Baseline score indicates an improvement.
Time frame: Baseline and Week 16
Percentage of Participants With a Modified Psoriatic Arthritis Response Criteria (PsARC) Response at Week 16
Modified PsARC response is defined as improvement in at least 2 of the 4 measures, at least one of which must be tender joint count or swollen joint count, and no worsening in any of the 4 measures: - 78 tender joint count, - 76 swollen joint count, - Patient global assessment of disease activity, measured on a 100 mm visual Analog scale (VAS), where 0 mm = lowest disease activity and 100 mm = highest; - Physician global assessment of disease activity, measured on a 100 mm VAS, where 0 mm = lowest disease activity and 100 mm = highest. Improvement or worsening in joint counts is defined as decrease or increase, respectively, from baseline by ≥ 30%, and improvement or worsening in global assessments is defined as decrease or increase, respectively, from baseline by ≥ 20 mm VAS.
Time frame: Baseline and Week 16
Change From Baseline in Patient's Assessment of Pain at Week 16
The participant was asked to place a vertical line on a 100-mm visual analog scale on which the left-hand boundary (score = 0 mm) represents "no pain," and the right-hand boundary (score = 100 mm) represents "pain as severe as can be imagined." The distance from the mark to the left-hand boundary was recorded in millimeters.
Time frame: Baseline and Week 16
Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 16
The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.
Time frame: Baseline and Week 16
Change From Baseline in Dactylitis Severity Score at Week 16
Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet will be rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.
Time frame: Baseline and Week 16
Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 16
The Clinical Disease Activity Index (CDAI) is a composite index that is calculated as the sum of the: - 28 tender joint count (TJC), - 28 swollen joint count (SJC), - Patient's Global Assessment of Disease Activity measured on a 10 cm visual analog scale (VAS), where 0 cm = lowest disease activity and 10 cm = highest; - Physician's Global Assessment of Disease Activity -measured on a 10 cm VAS, where 0 cm = lowest disease activity and 10 cm = highest. The CDAI score ranges from 0-76 where lower scores indicate less disease activity. The following thresholds of disease activity have been defined for the CDAI: Remission: ≤ 2.8 Low Disease Activity: \> 2.8 and ≤ 10 Moderate Disease Activity: \> 10 and ≤ 22 High Disease Activity: \> 22.
Time frame: Baseline and Week 16
Change From Baseline in the Disease Activity Score (DAS28) at Week 16
The DAS28 measures the severity of disease at a specific time and is derived from the following variables: - 28 tender joint count - 28 swollen joint count, which do not include the distal interphalangeal (DIP) joints, the hip joint, or the joints below the knee; - C-reactive protein (CRP) - Patient's global assessment of disease activity. DAS28(CRP) scores range from 0 to approximately 10, with the upper bound dependent on the highest possible level of CRP. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.
Time frame: Baseline and Week 16
Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 16
The FACIT-Fatigue scale is a 13-item self-administered questionnaire that assesses both the physical and functional consequences of fatigue. Each question is answered on a 5-point scale, where 0 means "not at all," and 4 means "very much." The FACIT-Fatigue scale score ranges from 0 to 52, with higher scores denoting lower levels of fatigue. A positive change from baseline score indicates an improvement.
Time frame: Baseline and Week 16
Change From Baseline in 36-item Short Form Health Survey (SF-36) Physical Functioning Domain at Week 24
The Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). Norm-based scores were used in analyses, calibrated so that 50 is the average score and the standard deviation equals 10. Higher scores indicate a higher level of functioning. The physical functioning domain assesses limitations in physical activities because of health problems. A positive change from Baseline score indicates an improvement.
Time frame: Baseline and Week 24
Percentage of Participants With a Modified Psoriatic Arthritis Response Criteria (PsARC) Response at Week 24
Modified PsARC response is defined as improvement in at least 2 of the 4 measures, at least one of which must be tender joint count or swollen joint count, and no worsening in any of the 4 measures: • 78 tender joint count, • 76 swollen joint count, • Patient global assessment of disease activity, measured on a 100 mm visual Analog scale (VAS), where 0 mm = lowest disease activity and 100 mm = highest; • Physician global assessment of disease activity, measured on a 100 mm VAS, where 0 mm = lowest disease activity and 100 mm = highest. Improvement or worsening in joint counts is defined as decrease or increase, respectively, from baseline by ≥ 30%, and improvement or worsening in global assessments is defined as decrease or increase, respectively, from baseline by ≥ 20 mm VAS.
Time frame: Baseline and Week 24
Change From Baseline in Patient's Assessment of Pain at Week 24
The participant was asked to place a vertical line on a 100-mm visual analog scale on which the left-hand boundary (score = 0 mm) represents "no pain," and the right-hand boundary (score = 100 mm) represents "pain as severe as can be imagined." The distance from the mark to the left-hand boundary was recorded in millimeters.
Time frame: Baseline and Week 24
Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 24
The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.
Time frame: Baseline and Week 24
Change From Baseline in Dactylitis Severity Score at Week 24
Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet will be rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.
Time frame: Baseline and Week 24
Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 24
The Clinical Disease Activity Index (CDAI) is a composite index that is calculated as the sum of the: • 28 tender joint count (TJC), • 28 swollen joint count (SJC), • Patient's Global Assessment of Disease Activity measured on a 10 cm visual analog scale (VAS), where 0 cm = lowest disease activity and 10 cm = highest; • Physician's Global Assessment of Disease Activity -measured on a 10 cm VAS, where 0 cm = lowest disease activity and 10 cm = highest. The CDAI score ranges from 0-76 where lower scores indicate less disease activity. The following thresholds of disease activity have been defined for the CDAI: Remission: ≤ 2.8; Low Disease Activity: \> 2.8 and ≤ 10; Moderate Disease Activity: \> 10 and ≤ 22; High Disease Activity: \> 22.
Time frame: Baseline and Week 24
Change From Baseline in the Disease Activity Score (DAS28) at Week 24
The DAS28 measures the severity of disease at a specific time and is derived from the following variables: • 28 tender joint count • 28 swollen joint count, which do not include the DIP joints, the hip joint, or the joints below the knee; • C-reactive protein (CRP) • Patient's global assessment of disease activity. DAS28(CRP) scores range from 0 to approximately 10, with the upper bound dependent on the highest possible level of CRP. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.
Time frame: Baseline and Week 24
Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 24
The FACIT-Fatigue scale is a 13-item self-administered questionnaire that assesses both the physical and functional consequences of fatigue. Each question is answered on a 5-point scale, where 0 means "not at all," and 4 means "very much." The FACIT-Fatigue scale score ranges from 0 to 52, with higher scores denoting lower levels of fatigue. A positive change from baseline score indicates an improvement.
Time frame: Baseline and Week 24
Percentage of Participants With MASES Improvement ≥ 20% at Week 16
Percentage of participants with pre-existing enthesopathy whose MASES improved by ≥ 20% from Baseline after 16 weeks of treatment. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.
Time frame: Baseline and Week 16
Percentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 16
Percentage of participants with pre-existing dactylitis whose dactylitis severity score improved by ≥ 1 after 16 weeks of treatment. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.
Time frame: Baseline and Week 16
Percentage of Participants With Good or Moderate European League Against Rheumatism (EULAR) Response at Week 16
A EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 of more than 1.2 compared with Baseline and attainment of a DAS28 score less than or equal to 3.2. A Moderate Response is defined as either: • an improvement (decrease) in the DAS28 of greater than 0.6 and less than or equal to 1.2 and attainment of a DAS28 score of less than or equal to 5.1 or, • an improvement (decrease) in the DAS28 of more than 1.2 and attainment of a DAS28 score of greater than 3.2.
Time frame: Baseline and Week 16
Percentage of Participants With MASES Improvement ≥ 20% at Week 24
Percentage of participants with pre-existing enthesopathy whose MASES improved by ≥ 20% from Baseline after 24 weeks of treatment. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.
Time frame: Baseline and Week 24
Percentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 24
Percentage of participants with pre-existing dactylitis whose dactylitis severity score improved by ≥ 1 after 24 weeks of treatment. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.
Time frame: Baseline and Week 24
Percentage of Participants With Good or Moderate EULAR Response at Week 24
EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 of more than 1.2 compared with Baseline and attainment of a DAS28 score less than or equal to 3.2. A Moderate Response is defined as either: • an improvement (decrease) in the DAS28 of greater than 0.6 and less than or equal to 1.2 and attainment of a DAS28 score of less than or equal to 5.1 or, • an improvement (decrease) in the DAS28 of more than 1.2 and attainment of a DAS28 score of greater than 3.2.
Time frame: Baseline and Week 24
Percentage of Participants With a ACR 50 Response at Week 16
Percentage of participants with an American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 50% improvement in 78 tender joint count; • ≥ 50% improvement in 76 swollen joint count; and • ≥ 50% improvement in at least 3 of the 5 following parameters: o Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); o Patient's global assessment of disease activity (measured on a 100 mm VAS); o Physician's global assessment of disease activity (measured on a 100 mm VAS); o Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); o C-Reactive Protein.
Time frame: Baseline and Week 16
Percentage of Participants With an ACR 70 Response at Week 16
Percentage of participants with an American College of Rheumatology 70% (ACR70) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 70% improvement in 78 tender joint count; • ≥ 70% improvement in 76 swollen joint count; and • ≥ 70% improvement in at least 3 of the 5 following parameters: o Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); o Patient's global assessment of disease activity (measured on a 100 mm VAS); o Physician's global assessment of disease activity (measured on a 100 mm VAS); o Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); o C-Reactive Protein.
Time frame: Baseline and Week 16
Percentage of Participants With an ACR 50 Response at Week 24
Percentage of participants with an American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 50% improvement in 78 tender joint count; • ≥ 50% improvement in 76 swollen joint count; and • ≥ 50% improvement in at least 3 of the 5 following parameters: o Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); o Patient's global assessment of disease activity (measured on a 100 mm VAS); o Physician's global assessment of disease activity (measured on a 100 mm VAS); o Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); o C-Reactive Protein.
Time frame: Baseline and Week 24
Percentage of Participants With a ACR 70 Response at Week 24
Percentage of participants with an American College of Rheumatology 70% (ACR70) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 70% improvement in 78 tender joint count; • ≥ 70% improvement in 76 swollen joint count; and • ≥ 70% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦C-Reactive Protein.
Time frame: Baseline and Week 24
Percentage of Participants Achieving a MASES Score of Zero at Week 16
Percentage of participants with pre-existing enthesopathy whose MASES improves to 0 after 16 weeks of treatment. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.
Time frame: Week 16
Percentage of Participants Achieving a Dactylitis Score of Zero at Week 16
Percentage of participants with pre-existing dactylitis whose dactylitis severity score improves to zero after 16 weeks of treatment. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.
Time frame: Week 16
Percentage of Participants Achieving a MASES Score of Zero at Week 24
Percentage of participants with pre-existing enthesopathy whose MASES improves to 0 after 24 weeks of treatment. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.
Time frame: Week 24
Percentage of Participants Achieving a Dactylitis Score of Zero at Week 24
Percentage of participants with pre-existing dactylitis whose dactylitis severity score improves to zero after 24 weeks of treatment. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.
Time frame: Week 24
Percentage of Participants With a ACR 20 Response at Week 52
Percentage of participants with an American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 20% improvement in 78 tender joint count; • ≥ 20% improvement in 76 swollen joint count; and • ≥ 20% improvement in at least 3 of the 5 following parameters: ◦Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦C-Reactive Protein. Two-sided 95% confidence interval is based on the Clopper-Pearson method.
Time frame: Baseline and Week 52
Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 52
The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire consisting of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task are summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement in functional ability.
Time frame: Baseline and Week 52
Change From Baseline in the SF-36 Physical Functioning Scale Score at Week 52
The Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). Norm-based scores were used in analyses, calibrated so that 50 is the average score and the standard deviation equals 10. Higher scores indicate a higher level of functioning. The physical functioning domain assesses limitations in physical activities because of health problems. A positive change from Baseline score indicates an improvement.
Time frame: Baseline and Week 52
Percentage of Participants With a Modified PsARC Response at Week 52
Modified PsARC response is defined as improvement in at least 2 of the 4 measures, at least one of which must be tender joint count or swollen joint count, and no worsening in any of the 4 measures: • 78 tender joint count, • 76 swollen joint count, • Patient global assessment of disease activity, measured on a 100 mm visual Analog scale (VAS), where 0 mm = lowest disease activity and 100 mm = highest; • Physician global assessment of disease activity, measured on a 100 mm VAS, where 0 mm = lowest disease activity and 100 mm = highest. Improvement or worsening in joint counts is defined as decrease or increase, respectively, from baseline by ≥ 30%, and improvement or worsening in global assessments is defined as decrease or increase, respectively, from baseline by ≥ 20 mm VAS. Two-sided 95% confidence interval is based on the Clopper-Pearson method.
Time frame: Baseline and Week 52
Change From Baseline in the Patient Assessment of Pain at Week 52
The participant was asked to place a vertical line on a 100-mm visual analog scale on which the left-hand boundary (score = 0 mm) represents "no pain," and the right-hand boundary (score = 100 mm) represents "pain as severe as can be imagined." The distance from the mark to the left-hand boundary was recorded in millimeters.
Time frame: Baseline and Week 52
Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 52
The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.
Time frame: Baseline and Week 52
Change From Baseline in the Dactylitis Severity Score at Week 52
Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet will be rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.
Time frame: Baseline and Week 52
Change From Baseline in the CDAI Score at Week 52
The Clinical Disease Activity Index (CDAI) is a composite index that is calculated as the sum of the: • 28 tender joint count (TJC), • 28 swollen joint count (SJC), • Patient's Global Assessment of Disease Activity measured on a 10 cm visual analog scale (VAS), where 0 cm = lowest disease activity and 10 cm = highest; • Physician's Global Assessment of Disease Activity -measured on a 10 cm VAS, where 0 cm = lowest disease activity and 10 cm = highest. The CDAI score ranges from 0-76 where lower scores indicate less disease activity. The following thresholds of disease activity have been defined for the CDAI: Remission: ≤ 2.8 Low Disease Activity: \> 2.8 and ≤ 10 Moderate Disease Activity: \> 10 and ≤ 22 High Disease Activity: \> 22.
Time frame: Baseline and Week 52
Change From Baseline in the DAS28 at Week 52
The DAS28 measures the severity of disease at a specific time and is derived from the following variables: • 28 tender joint count • 28 swollen joint count, which do not include the DIP joints, the hip joint, or the joints below the knee; • C-reactive protein (CRP) • Patient's global assessment of disease activity. DAS28(CRP) scores range from 0 to approximately 10, with the upper bound dependent on the highest possible level of CRP. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.
Time frame: Baseline and Week 52
Change From Baseline in the FACIT-Fatigue Scale Score at Week 52
The FACIT-Fatigue scale is a 13-item self-administered questionnaire that assesses both the physical and functional consequences of fatigue. Each question is answered on a 5-point scale, where 0 means "not at all," and 4 means "very much." The FACIT-Fatigue scale score ranges from 0 to 52, with higher scores denoting lower levels of fatigue. A positive change from baseline score indicates an improvement.
Time frame: Baseline and Week 52
Percentage of Participants With MASES Improvement ≥ 20% at Week 52
Percentage of participants with pre-existing enthesopathy whose MASES improved by ≥ 20% from Baseline after 52 weeks. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses. Two-sided 95% confidence interval is based on the Clopper-Pearson method.
Time frame: Baseline and Week 52
Percentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 52
Percentage of participants with pre-existing dactylitis whose dactylitis severity score improved by ≥ 1 after 52 weeks. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present. Two-sided 95% confidence interval is based on the Clopper-Pearson method.
Time frame: Baseline and Week 52
Percentage of Participants Achieving Good or Moderate EULAR Response at Week 52
A EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 of more than 1.2 compared with Baseline and attainment of a DAS28 score less than or equal to 3.2. A Moderate Response is defined as either: • an improvement (decrease) in the DAS28 of greater than 0.6 and less than or equal to 1.2 and attainment of a DAS28 score of less than or equal to 5.1 or, • an improvement (decrease) in the DAS28 of more than 1.2 and attainment of a DAS28 score of greater than 3.2.
Time frame: Baseline and Week 52
Percentage of Participants With an ACR 50 Response at Week 52
Percentage of participants with an American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 50% improvement in 78 tender joint count; • ≥ 50% improvement in 76 swollen joint count; and • ≥ 50% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦C-Reactive Protein. Two-sided 95% confidence interval is based on the Clopper-Pearson method.
Time frame: Baseline and Week 52
Percentage of Participants With an ACR 70 Response at Week 52
Percentage of participants with an American College of Rheumatology 70% (ACR70) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 70% improvement in 78 tender joint count; • ≥ 70% improvement in 76 swollen joint count; and • ≥ 70% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦ C-Reactive Protein. Two-sided 95% confidence interval is based on the Clopper-Pearson method.
Time frame: Baseline and Week 52
Percentage of Participants Achieving a MASES Score of Zero at Week 52
Percentage of participants with pre-existing enthesopathy whose MASES improves to 0 after 24 weeks. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses. Two-sided 95% confidence interval is based on the Clopper-Pearson method.
Time frame: Week 52
Percentage of Participants Achieving a Dactylitis Score of Zero at Week 52
Percentage of participants with pre-existing dactylitis whose dactylitis severity score improves to zero after 52 weeks. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present. Two-sided 95% confidence interval is based on the Clopper-Pearson method.
Time frame: Week 52
Number of Participants With Treatment Emergent Adverse Events During the Placebo-Controlled Phase
A treatment emergent adverse event (TEAE) is an AE with a start date on or after the date of the first dose of Investigational Product (IP). The severity of each adverse event (AE) and serious AE (SAE) was assessed by the investigator and graded based on a scale from Mild - mild symptoms to Severe AEs (non-serious or serious). A serious adverse event (SAE) is any AE which: * Resulted in death * Was life-threatening * Required inpatient hospitalization or prolongation of existing hospitalization * Resulted in persistent or significant disability/incapacity * Was a congenital anomaly/birth defect * Constituted an important medical event
Time frame: Week 0 to Week 16 for placebo participants who entered EE at Week 16 and up to Week 24 for all other participants (placebo participants who remained on placebo through week 24 and participants randomized to the APR 20 mg BID or APR 30 mg BID)
Number of Participants With TEAEs During the Apremilast-Exposure Period
A treatment emergent adverse event (TEAE) is an AE with a start date on or after the date of the first dose of Investigational Product (IP). The severity of each adverse event (AE) and serious AE (SAE) was assessed by the investigator and graded based on a scale from Mild - mild symptoms to Severe AEs (non-serious or serious). A serious adverse event (SAE) is any AE which: * Resulted in death * Was life-threatening * Required inpatient hospitalization or prolongation of existing hospitalization * Resulted in persistent or significant disability/incapacity * Was a congenital anomaly/birth defect * Constituted an important medical event
Time frame: Week 0 to week 260; overall median duration of exposure to apremilast 20 mg and 30 mg BID was 198 weeks
This study was a multicenter study with 84 sites from the United States, Canada, Europe, Russia, Australia, South Africa and Taiwan.
| Milestone | Placebo | Apremilast 20 mg | Apremilast 30 mg | Placebo / Apremilast 20 mg EE | Placebo / Apremilast 20 mg XO | Placebo / Apremilast 30 mg EE | Placebo / Apremilast 30 mg XO | Placebo/Apremilast 20 mg (Long-Term Safety Phase) | Placebo/Apremilast 30 mg (Long-Term Safety Phase) |
|---|---|---|---|---|---|---|---|---|---|
| Started | 162 | 163 | 163 | 0 | 0 | 0 | 0 | 0 | 0 |
| Received treatment | 159 | 163 | 162 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed week 16 | 148 | 151 | 149 | 0 | 0 | 0 | 0 | 0 | 0 |
| Early escape at week 16 | 88 | 59 | 64 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 143 | 143 | 142 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 19 | 20 | 21 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 4 | 5 | 12 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 3 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 7 | 9 | 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Randomization error | 3 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo | Apremilast 20 mg | Apremilast 30 mg | Placebo / Apremilast 20 mg EE | Placebo / Apremilast 20 mg XO | Placebo / Apremilast 30 mg EE | Placebo / Apremilast 30 mg XO | Placebo/Apremilast 20 mg (Long-Term Safety Phase) | Placebo/Apremilast 30 mg (Long-Term Safety Phase) |
|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 137 | 134 | 43 | 27 | 41 | 28 | 0 | 0 |
| Completed | 0 | 125 | 114 | 35 | 25 | 34 | 28 | 0 | 0 |
| Not completed | 0 | 12 | 20 | 8 | 2 | 7 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 2 | 3 | 1 | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 5 | 7 | 4 | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Non-compliance with study drug | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 3 | 7 | 3 | 1 | 3 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo | Apremilast 20 mg | Apremilast 30 mg | Placebo / Apremilast 20 mg EE | Placebo / Apremilast 20 mg XO | Placebo / Apremilast 30 mg EE | Placebo / Apremilast 30 mg XO | Placebo/Apremilast 20 mg (Long-Term Safety Phase) | Placebo/Apremilast 30 mg (Long-Term Safety Phase) |
|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 119 | 109 | 0 | 0 | 0 | 0 | 58 | 60 |
| Completed | 0 | 107 | 95 | 0 | 0 | 0 | 0 | 48 | 51 |
| Not completed | 0 | 12 | 14 | 0 | 0 | 0 | 0 | 10 | 9 |
| Withdrew: Miscellaneous | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 2 | 2 |
| Withdrew: Lack of efficacy | 0 | 4 | 2 | 0 | 0 | 0 | 0 | 4 | 0 |
| Withdrew: Withdrawal by subject | 0 | 7 | 9 | 0 | 0 | 0 | 0 | 4 | 6 |
| Withdrew: Lost to follow-up | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo | Apremilast 20 mg | Apremilast 30 mg | Placebo / Apremilast 20 mg EE | Placebo / Apremilast 20 mg XO | Placebo / Apremilast 30 mg EE | Placebo / Apremilast 30 mg XO | Placebo/Apremilast 20 mg (Long-Term Safety Phase) | Placebo/Apremilast 30 mg (Long-Term Safety Phase) |
|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 107 | 95 | 0 | 0 | 0 | 0 | 48 | 51 |
| Completed | 0 | 89 | 84 | 0 | 0 | 0 | 0 | 42 | 46 |
| Not completed | 0 | 18 | 11 | 0 | 0 | 0 | 0 | 6 | 5 |
| Withdrew: Adverse event | 0 | 4 | 1 | 0 | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Lack of efficacy | 0 | 8 | 5 | 0 | 0 | 0 | 0 | 3 | 1 |
| Withdrew: Non-compliance with study drug | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 5 | 1 | 0 | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Miscellaneous | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 2 |
| Milestone | Placebo | Apremilast 20 mg | Apremilast 30 mg | Placebo / Apremilast 20 mg EE | Placebo / Apremilast 20 mg XO | Placebo / Apremilast 30 mg EE | Placebo / Apremilast 30 mg XO | Placebo/Apremilast 20 mg (Long-Term Safety Phase) | Placebo/Apremilast 30 mg (Long-Term Safety Phase) |
|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 89 | 84 | 0 | 0 | 0 | 0 | 41 | 46 |
| Completed | 0 | 80 | 77 | 0 | 0 | 0 | 0 | 37 | 39 |
| Not completed | 0 | 9 | 7 | 0 | 0 | 0 | 0 | 4 | 7 |
| Withdrew: Miscellaneous | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Lack of efficacy | 0 | 2 | 2 | 0 | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 4 | 2 | 0 | 0 | 0 | 0 | 1 | 3 |
| Withdrew: Death | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Milestone | Placebo | Apremilast 20 mg | Apremilast 30 mg | Placebo / Apremilast 20 mg EE | Placebo / Apremilast 20 mg XO | Placebo / Apremilast 30 mg EE | Placebo / Apremilast 30 mg XO | Placebo/Apremilast 20 mg (Long-Term Safety Phase) | Placebo/Apremilast 30 mg (Long-Term Safety Phase) |
|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 80 | 77 | 0 | 0 | 0 | 0 | 38 | 39 |
| Completed | 0 | 72 | 69 | 0 | 0 | 0 | 0 | 33 | 37 |
| Not completed | 0 | 8 | 8 | 0 | 0 | 0 | 0 | 5 | 2 |
| Withdrew: Withdrawal by subject | 0 | 3 | 3 | 0 | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Adverse event | 0 | 2 | 2 | 0 | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Lack of efficacy | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 2 | 1 |
| Withdrew: Non-compliance with study drug | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Miscellaneous | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
Percentage of participants with an ACR20 response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 20% improvement in 78 tender joint count; • ≥ 20% improvement in 76 swollen joint count; and • ≥ 20% improvement in at least 3 of the 5 following parameters: ◦Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦C-Reactive Protein.
| percentage of participants | Placebo | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|
| Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16 | 18.9 | 37.4 | 32.1 |
The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire consisting of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task are summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement in functional ability.
| units on a scale | Placebo | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|
| Change From Baseline in Health Assessment Questionnaire- Disability Index (HAQ-DI) at Week 16 | -0.053 ± 0.0358 | -0.157 ± 0.0351 | -0.193 ± 0.0354 |
Percentage of participants with an American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 20% improvement in 78 tender joint count; • ≥ 20% improvement in 76 swollen joint count; and • ≥ 20% improvement in at least 3 of the 5 following parameters: ◦Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦C-Reactive Protein.
| percentage of participants | Placebo | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|
| Percentage of Participants With an ACR 20 Response at Week 24 | 15.7 | 31.3 | 24.7 |
The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire consisting of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task are summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement in functional ability.
| units on a scale | Placebo | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|
| Change From Baseline in Health Assessment Questionnaire- Disability Index (HAQ-DI) at Week 24 | -0.085 ± 0.0377 | -0.165 ± 0.0370 | -0.206 ± 0.0372 |
The Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). Norm-based scores were used in analyses, calibrated so that 50 is the average score and the standard deviation equals 10. Higher scores indicate a higher level of functioning. The physical functioning domain assesses limitations in physical activities because of health problems. A positive change from Baseline score indicates an improvement.
| units on a scale | Placebo | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|
| Change From Baseline in 36-item Short Form Health Survey (SF-36) Physical Functioning Domain at Week 16 | 0.81 ± 0.678 | 2.17 ± 0.664 | 2.91 ± 0.671 |
Modified PsARC response is defined as improvement in at least 2 of the 4 measures, at least one of which must be tender joint count or swollen joint count, and no worsening in any of the 4 measures: - 78 tender joint count, - 76 swollen joint count, - Patient global assessment of disease activity, measured on a 100 mm visual Analog scale (VAS), where 0 mm = lowest disease activity and 100 mm = highest; - Physician global assessment of disease activity, measured on a 100 mm VAS, where 0 mm = lowest disease activity and 100 mm = highest. Improvement or worsening in joint counts is defined as decrease or increase, respectively, from baseline by ≥ 30%, and improvement or worsening in global assessments is defined as decrease or increase, respectively, from baseline by ≥ 20 mm VAS.
| percentage of participants | Placebo | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|
| Percentage of Participants With a Modified Psoriatic Arthritis Response Criteria (PsARC) Response at Week 16 | 33.3 | 47.9 | 48.1 |
The participant was asked to place a vertical line on a 100-mm visual analog scale on which the left-hand boundary (score = 0 mm) represents "no pain," and the right-hand boundary (score = 100 mm) represents "pain as severe as can be imagined." The distance from the mark to the left-hand boundary was recorded in millimeters.
| mm | Placebo | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|
| Change From Baseline in Patient's Assessment of Pain at Week 16 | -7.0 ± 1.93 | -12.5 ± 1.89 | -11.9 ± 1.90 |
The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.
| units on a scale | Placebo | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|
| Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 16 | -1.0 ± 0.29 | -0.9 ± 0.28 | -1.4 ± 0.29 |
Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet will be rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.
| units on a scale | Placebo | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|
| Change From Baseline in Dactylitis Severity Score at Week 16 | -1.1 ± 0.28 | -0.8 ± 0.26 | -1.3 ± 0.26 |
The Clinical Disease Activity Index (CDAI) is a composite index that is calculated as the sum of the: - 28 tender joint count (TJC), - 28 swollen joint count (SJC), - Patient's Global Assessment of Disease Activity measured on a 10 cm visual analog scale (VAS), where 0 cm = lowest disease activity and 10 cm = highest; - Physician's Global Assessment of Disease Activity -measured on a 10 cm VAS, where 0 cm = lowest disease activity and 10 cm = highest. The CDAI score ranges from 0-76 where lower scores indicate less disease activity. The following thresholds of disease activity have been defined for the CDAI: Remission: ≤ 2.8 Low Disease Activity: \> 2.8 and ≤ 10 Moderate Disease Activity: \> 10 and ≤ 22 High Disease Activity: \> 22.
| units on a scale | Placebo | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|
| Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 16 | -3.30 ± 0.871 | -7.75 ± 0.851 | -6.81 ± 0.869 |
The DAS28 measures the severity of disease at a specific time and is derived from the following variables: - 28 tender joint count - 28 swollen joint count, which do not include the distal interphalangeal (DIP) joints, the hip joint, or the joints below the knee; - C-reactive protein (CRP) - Patient's global assessment of disease activity. DAS28(CRP) scores range from 0 to approximately 10, with the upper bound dependent on the highest possible level of CRP. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.
| units on a scale | Placebo | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|
| Change From Baseline in the Disease Activity Score (DAS28) at Week 16 | -0.27 ± 0.082 | -0.74 ± 0.080 | -0.67 ± 0.080 |
The FACIT-Fatigue scale is a 13-item self-administered questionnaire that assesses both the physical and functional consequences of fatigue. Each question is answered on a 5-point scale, where 0 means "not at all," and 4 means "very much." The FACIT-Fatigue scale score ranges from 0 to 52, with higher scores denoting lower levels of fatigue. A positive change from baseline score indicates an improvement.
| units on a scale | Placebo | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|
| Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 16 | 0.63 ± 0.724 | 0.91 ± 0.712 | 2.75 ± 0.715 |
The Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). Norm-based scores were used in analyses, calibrated so that 50 is the average score and the standard deviation equals 10. Higher scores indicate a higher level of functioning. The physical functioning domain assesses limitations in physical activities because of health problems. A positive change from Baseline score indicates an improvement.
| units on a scale | Placebo | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|
| Change From Baseline in 36-item Short Form Health Survey (SF-36) Physical Functioning Domain at Week 24 | 1.44 ± 0.688 | 2.97 ± 0.673 | 3.30 ± 0.679 |
Modified PsARC response is defined as improvement in at least 2 of the 4 measures, at least one of which must be tender joint count or swollen joint count, and no worsening in any of the 4 measures: • 78 tender joint count, • 76 swollen joint count, • Patient global assessment of disease activity, measured on a 100 mm visual Analog scale (VAS), where 0 mm = lowest disease activity and 100 mm = highest; • Physician global assessment of disease activity, measured on a 100 mm VAS, where 0 mm = lowest disease activity and 100 mm = highest. Improvement or worsening in joint counts is defined as decrease or increase, respectively, from baseline by ≥ 30%, and improvement or worsening in global assessments is defined as decrease or increase, respectively, from baseline by ≥ 20 mm VAS.
| percentage of participants | Placebo | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|
| Percentage of Participants With a Modified Psoriatic Arthritis Response Criteria (PsARC) Response at Week 24 | 24.5 | 39.9 | 32.1 |
The participant was asked to place a vertical line on a 100-mm visual analog scale on which the left-hand boundary (score = 0 mm) represents "no pain," and the right-hand boundary (score = 100 mm) represents "pain as severe as can be imagined." The distance from the mark to the left-hand boundary was recorded in millimeters.
| mm | Placebo | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|
| Change From Baseline in Patient's Assessment of Pain at Week 24 | -8.0 ± 1.90 | -11.5 ± 1.86 | -9.7 ± 1.88 |
The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.
| units on a scale | Placebo | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|
| Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 24 | -0.9 ± 0.29 | -0.9 ± 0.28 | -1.3 ± 0.29 |
Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet will be rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.
| units on a scale | Placebo | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|
| Change From Baseline in Dactylitis Severity Score at Week 24 | -1.1 ± 0.27 | -0.9 ± 0.25 | -1.4 ± 0.26 |
The Clinical Disease Activity Index (CDAI) is a composite index that is calculated as the sum of the: • 28 tender joint count (TJC), • 28 swollen joint count (SJC), • Patient's Global Assessment of Disease Activity measured on a 10 cm visual analog scale (VAS), where 0 cm = lowest disease activity and 10 cm = highest; • Physician's Global Assessment of Disease Activity -measured on a 10 cm VAS, where 0 cm = lowest disease activity and 10 cm = highest. The CDAI score ranges from 0-76 where lower scores indicate less disease activity. The following thresholds of disease activity have been defined for the CDAI: Remission: ≤ 2.8; Low Disease Activity: \> 2.8 and ≤ 10; Moderate Disease Activity: \> 10 and ≤ 22; High Disease Activity: \> 22.
| units on a scale | Placebo | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|
| Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 24 | -3.21 ± 0.884 | -7.71 ± 0.864 | -6.35 ± 0.878 |
The DAS28 measures the severity of disease at a specific time and is derived from the following variables: • 28 tender joint count • 28 swollen joint count, which do not include the DIP joints, the hip joint, or the joints below the knee; • C-reactive protein (CRP) • Patient's global assessment of disease activity. DAS28(CRP) scores range from 0 to approximately 10, with the upper bound dependent on the highest possible level of CRP. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.
| units on a scale | Placebo | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|
| Change From Baseline in the Disease Activity Score (DAS28) at Week 24 | -0.27 ± 0.084 | -0.73 ± 0.082 | -0.65 ± 0.083 |
The FACIT-Fatigue scale is a 13-item self-administered questionnaire that assesses both the physical and functional consequences of fatigue. Each question is answered on a 5-point scale, where 0 means "not at all," and 4 means "very much." The FACIT-Fatigue scale score ranges from 0 to 52, with higher scores denoting lower levels of fatigue. A positive change from baseline score indicates an improvement.
| units on a scale | Placebo | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|
| Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 24 | 0.52 ± 0.721 | 0.68 ± 0.710 | 2.65 ± 0.713 |
Percentage of participants with pre-existing enthesopathy whose MASES improved by ≥ 20% from Baseline after 16 weeks of treatment. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.
| percentage of participants | Placebo | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|
| Percentage of Participants With MASES Improvement ≥ 20% at Week 16 | 52.9 | 54.2 | 56.4 |
Percentage of participants with pre-existing dactylitis whose dactylitis severity score improved by ≥ 1 after 16 weeks of treatment. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.
| percentage of participants | Placebo | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|
| Percentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 16 | 59.1 | 62.3 | 61.6 |
A EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 of more than 1.2 compared with Baseline and attainment of a DAS28 score less than or equal to 3.2. A Moderate Response is defined as either: • an improvement (decrease) in the DAS28 of greater than 0.6 and less than or equal to 1.2 and attainment of a DAS28 score of less than or equal to 5.1 or, • an improvement (decrease) in the DAS28 of more than 1.2 and attainment of a DAS28 score of greater than 3.2.
| percentage of participants | Placebo | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|
| Percentage of Participants With Good or Moderate European League Against Rheumatism (EULAR) Response at Week 16 | 31.4 | 53.4 | 48.8 |
Percentage of participants with pre-existing enthesopathy whose MASES improved by ≥ 20% from Baseline after 24 weeks of treatment. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.
| percentage of participants | Placebo | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|
| Percentage of Participants With MASES Improvement ≥ 20% at Week 24 | 51.0 | 57.0 | 57.4 |
Percentage of participants with pre-existing dactylitis whose dactylitis severity score improved by ≥ 1 after 24 weeks of treatment. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.
| percentage of participants | Placebo | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|
| Percentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 24 | 62.1 | 68.8 | 68.5 |
EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 of more than 1.2 compared with Baseline and attainment of a DAS28 score less than or equal to 3.2. A Moderate Response is defined as either: • an improvement (decrease) in the DAS28 of greater than 0.6 and less than or equal to 1.2 and attainment of a DAS28 score of less than or equal to 5.1 or, • an improvement (decrease) in the DAS28 of more than 1.2 and attainment of a DAS28 score of greater than 3.2.
| percentage of participants | Placebo | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|
| Percentage of Participants With Good or Moderate EULAR Response at Week 24 | 21.4 | 41.7 | 33.3 |
Percentage of participants with an American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 50% improvement in 78 tender joint count; • ≥ 50% improvement in 76 swollen joint count; and • ≥ 50% improvement in at least 3 of the 5 following parameters: o Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); o Patient's global assessment of disease activity (measured on a 100 mm VAS); o Physician's global assessment of disease activity (measured on a 100 mm VAS); o Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); o C-Reactive Protein.
| percentage of participants | Placebo | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|
| Percentage of Participants With a ACR 50 Response at Week 16 | 5.0 | 14.7 | 10.5 |
Percentage of participants with an American College of Rheumatology 70% (ACR70) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 70% improvement in 78 tender joint count; • ≥ 70% improvement in 76 swollen joint count; and • ≥ 70% improvement in at least 3 of the 5 following parameters: o Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); o Patient's global assessment of disease activity (measured on a 100 mm VAS); o Physician's global assessment of disease activity (measured on a 100 mm VAS); o Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); o C-Reactive Protein.
| percentage of participants | Placebo | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|
| Percentage of Participants With an ACR 70 Response at Week 16 | 0.6 | 3.7 | 1.2 |
Percentage of participants with an American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 50% improvement in 78 tender joint count; • ≥ 50% improvement in 76 swollen joint count; and • ≥ 50% improvement in at least 3 of the 5 following parameters: o Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); o Patient's global assessment of disease activity (measured on a 100 mm VAS); o Physician's global assessment of disease activity (measured on a 100 mm VAS); o Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); o C-Reactive Protein.
| percentage of participants | Placebo | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|
| Percentage of Participants With an ACR 50 Response at Week 24 | 8.8 | 14.1 | 11.7 |
Percentage of participants with an American College of Rheumatology 70% (ACR70) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 70% improvement in 78 tender joint count; • ≥ 70% improvement in 76 swollen joint count; and • ≥ 70% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦C-Reactive Protein.
| percentage of participants | Placebo | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|
| Percentage of Participants With a ACR 70 Response at Week 24 | 3.1 | 5.5 | 2.5 |
Percentage of participants with pre-existing enthesopathy whose MASES improves to 0 after 16 weeks of treatment. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.
| percentage of participants | Placebo | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|
| Percentage of Participants Achieving a MASES Score of Zero at Week 16 | 23.1 | 29.0 | 20.8 |
Percentage of participants with pre-existing dactylitis whose dactylitis severity score improves to zero after 16 weeks of treatment. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.
| percentage of participants | Placebo | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|
| Percentage of Participants Achieving a Dactylitis Score of Zero at Week 16 | 40.9 | 42.9 | 41.1 |
Percentage of participants with pre-existing enthesopathy whose MASES improves to 0 after 24 weeks of treatment. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.
| percentage of participants | Placebo | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|
| Percentage of Participants Achieving a MASES Score of Zero at Week 24 | 24.0 | 29.9 | 22.8 |
Percentage of participants with pre-existing dactylitis whose dactylitis severity score improves to zero after 24 weeks of treatment. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.
| percentage of participants | Placebo | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|
| Percentage of Participants Achieving a Dactylitis Score of Zero at Week 24 | 40.9 | 44.2 | 46.6 |
Percentage of participants with an American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 20% improvement in 78 tender joint count; • ≥ 20% improvement in 76 swollen joint count; and • ≥ 20% improvement in at least 3 of the 5 following parameters: ◦Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦C-Reactive Protein. Two-sided 95% confidence interval is based on the Clopper-Pearson method.
| percentage of participants | Placebo / Apremilast 20 mg | Placebo / Apremilast 30 mg | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|---|
| Percentage of Participants With a ACR 20 Response at Week 52 | 53.3 (40.0 to 66.3) | 47.5 (34.6 to 60.7) | 52.9 (43.6 to 62.0) | 52.6 (43.1 to 61.9) |
The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire consisting of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task are summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement in functional ability.
| units on a scale | Placebo / Apremilast 20 mg | Placebo / Apremilast 30 mg | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|---|
| Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 52 | -0.208 ± 0.4831 | -0.310 ± 0.5990 | -0.192 ± 0.5729 | -0.330 ± 0.5089 |
The Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). Norm-based scores were used in analyses, calibrated so that 50 is the average score and the standard deviation equals 10. Higher scores indicate a higher level of functioning. The physical functioning domain assesses limitations in physical activities because of health problems. A positive change from Baseline score indicates an improvement.
| units on a scale | Placebo / Apremilast 20 mg | Placebo / Apremilast 30 mg | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|---|
| Change From Baseline in the SF-36 Physical Functioning Scale Score at Week 52 | 4.13 ± 9.106 | 5.97 ± 9.612 | 4.05 ± 8.752 | 4.97 ± 9.656 |
Modified PsARC response is defined as improvement in at least 2 of the 4 measures, at least one of which must be tender joint count or swollen joint count, and no worsening in any of the 4 measures: • 78 tender joint count, • 76 swollen joint count, • Patient global assessment of disease activity, measured on a 100 mm visual Analog scale (VAS), where 0 mm = lowest disease activity and 100 mm = highest; • Physician global assessment of disease activity, measured on a 100 mm VAS, where 0 mm = lowest disease activity and 100 mm = highest. Improvement or worsening in joint counts is defined as decrease or increase, respectively, from baseline by ≥ 30%, and improvement or worsening in global assessments is defined as decrease or increase, respectively, from baseline by ≥ 20 mm VAS. Two-sided 95% confidence interval is based on the Clopper-Pearson method.
| percentage of participants | Placebo / Apremilast 20 mg | Placebo / Apremilast 30 mg | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|---|
| Percentage of Participants With a Modified PsARC Response at Week 52 | 78.3 (65.8 to 87.9) | 73.3 (60.3 to 83.9) | 72.4 (63.6 to 80.0) | 74.6 (65.6 to 82.3) |
The participant was asked to place a vertical line on a 100-mm visual analog scale on which the left-hand boundary (score = 0 mm) represents "no pain," and the right-hand boundary (score = 100 mm) represents "pain as severe as can be imagined." The distance from the mark to the left-hand boundary was recorded in millimeters.
| mm | Placebo / Apremilast 20 mg | Placebo / Apremilast 30 mg | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|---|
| Change From Baseline in the Patient Assessment of Pain at Week 52 | -15.6 ± 23.77 | -16.0 ± 24.48 | -13.5 ± 27.78 | -12.9 ± 26.54 |
The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.
| units on a scale | Placebo / Apremilast 20 mg | Placebo / Apremilast 30 mg | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|---|
| Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 52 | -2.5 ± 4.41 | -2.5 ± 2.73 | -1.7 ± 3.12 | -2.1 ± 2.82 |
Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet will be rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.
| units on a scale | Placebo / Apremilast 20 mg | Placebo / Apremilast 30 mg | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|---|
| Change From Baseline in the Dactylitis Severity Score at Week 52 | -1.9 ± 1.14 | -2.1 ± 2.32 | -1.8 ± 1.98 | -1.8 ± 2.06 |
The Clinical Disease Activity Index (CDAI) is a composite index that is calculated as the sum of the: • 28 tender joint count (TJC), • 28 swollen joint count (SJC), • Patient's Global Assessment of Disease Activity measured on a 10 cm visual analog scale (VAS), where 0 cm = lowest disease activity and 10 cm = highest; • Physician's Global Assessment of Disease Activity -measured on a 10 cm VAS, where 0 cm = lowest disease activity and 10 cm = highest. The CDAI score ranges from 0-76 where lower scores indicate less disease activity. The following thresholds of disease activity have been defined for the CDAI: Remission: ≤ 2.8 Low Disease Activity: \> 2.8 and ≤ 10 Moderate Disease Activity: \> 10 and ≤ 22 High Disease Activity: \> 22.
| units on a scale | Placebo / Apremilast 20 mg | Placebo / Apremilast 30 mg | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|---|
| Change From Baseline in the CDAI Score at Week 52 | -13.66 ± 9.811 | -13.13 ± 13.148 | -12.03 ± 10.492 | -14.38 ± 11.531 |
The DAS28 measures the severity of disease at a specific time and is derived from the following variables: • 28 tender joint count • 28 swollen joint count, which do not include the DIP joints, the hip joint, or the joints below the knee; • C-reactive protein (CRP) • Patient's global assessment of disease activity. DAS28(CRP) scores range from 0 to approximately 10, with the upper bound dependent on the highest possible level of CRP. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.
| units on a scale | Placebo / Apremilast 20 mg | Placebo / Apremilast 30 mg | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|---|
| Change From Baseline in the DAS28 at Week 52 | -1.18 ± 1.015 | -1.18 ± 1.366 | -1.11 ± 1.059 | -1.30 ± 1.033 |
The FACIT-Fatigue scale is a 13-item self-administered questionnaire that assesses both the physical and functional consequences of fatigue. Each question is answered on a 5-point scale, where 0 means "not at all," and 4 means "very much." The FACIT-Fatigue scale score ranges from 0 to 52, with higher scores denoting lower levels of fatigue. A positive change from baseline score indicates an improvement.
| units on a scale | Placebo / Apremilast 20 mg | Placebo / Apremilast 30 mg | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|---|
| Change From Baseline in the FACIT-Fatigue Scale Score at Week 52 | 1.97 ± 8.544 | 4.95 ± 9.414 | 2.45 ± 9.481 | 4.38 ± 9.847 |
Percentage of participants with pre-existing enthesopathy whose MASES improved by ≥ 20% from Baseline after 52 weeks. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses. Two-sided 95% confidence interval is based on the Clopper-Pearson method.
| percentage of participants | Placebo / Apremilast 20 mg | Placebo / Apremilast 30 mg | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|---|
| Percentage of Participants With MASES Improvement ≥ 20% at Week 52 | 72.5 (56.1 to 85.4) | 79.5 (63.5 to 90.7) | 70.0 (58.7 to 79.7) | 69.2 (57.8 to 79.2) |
Percentage of participants with pre-existing dactylitis whose dactylitis severity score improved by ≥ 1 after 52 weeks. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present. Two-sided 95% confidence interval is based on the Clopper-Pearson method.
| percentage of participants | Placebo / Apremilast 20 mg | Placebo / Apremilast 30 mg | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|---|
| Percentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 52 | 95.7 (78.1 to 99.9) | 88.9 (70.8 to 97.6) | 80.7 (68.1 to 90.0) | 85.0 (73.4 to 92.9) |
A EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 of more than 1.2 compared with Baseline and attainment of a DAS28 score less than or equal to 3.2. A Moderate Response is defined as either: • an improvement (decrease) in the DAS28 of greater than 0.6 and less than or equal to 1.2 and attainment of a DAS28 score of less than or equal to 5.1 or, • an improvement (decrease) in the DAS28 of more than 1.2 and attainment of a DAS28 score of greater than 3.2.
| percentage of participants | Placebo / Apremilast 20 mg | Placebo / Apremilast 30 mg | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|---|
| Percentage of Participants Achieving Good or Moderate EULAR Response at Week 52 | 70.0 | 64.5 | 68.0 | 67.5 |
Percentage of participants with an American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 50% improvement in 78 tender joint count; • ≥ 50% improvement in 76 swollen joint count; and • ≥ 50% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦C-Reactive Protein. Two-sided 95% confidence interval is based on the Clopper-Pearson method.
| percentage of participants | Placebo / Apremilast 20 mg | Placebo / Apremilast 30 mg | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|---|
| Percentage of Participants With an ACR 50 Response at Week 52 | 30.5 (19.2 to 43.9) | 27.4 (16.9 to 40.2) | 26.7 (19.0 to 35.5) | 18.6 (12.1 to 26.9) |
Percentage of participants with an American College of Rheumatology 70% (ACR70) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 70% improvement in 78 tender joint count; • ≥ 70% improvement in 76 swollen joint count; and • ≥ 70% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦ C-Reactive Protein. Two-sided 95% confidence interval is based on the Clopper-Pearson method.
| percentage of participants | Placebo / Apremilast 20 mg | Placebo / Apremilast 30 mg | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|---|
| Percentage of Participants With an ACR 70 Response at Week 52 | 16.9 (8.4 to 29.0) | 14.3 (6.7 to 25.4) | 9.8 (5.1 to 16.4) | 6.8 (3.0 to 12.9) |
Percentage of participants with pre-existing enthesopathy whose MASES improves to 0 after 24 weeks. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses. Two-sided 95% confidence interval is based on the Clopper-Pearson method.
| percentage of participants | Placebo / Apremilast 20 mg | Placebo / Apremilast 30 mg | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|---|
| Percentage of Participants Achieving a MASES Score of Zero at Week 52 | 42.5 (27.0 to 59.1) | 41.0 (25.6 to 57.9) | 40.0 (29.2 to 51.6) | 37.2 (26.5 to 48.9) |
Percentage of participants with pre-existing dactylitis whose dactylitis severity score improves to zero after 52 weeks. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present. Two-sided 95% confidence interval is based on the Clopper-Pearson method.
| percentage of participants | Placebo / Apremilast 20 mg | Placebo / Apremilast 30 mg | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|---|
| Percentage of Participants Achieving a Dactylitis Score of Zero at Week 52 | 78.3 (56.3 to 92.5) | 77.8 (57.7 to 91.4) | 57.9 (44.1 to 70.9) | 65.0 (51.6 to 76.9) |
A treatment emergent adverse event (TEAE) is an AE with a start date on or after the date of the first dose of Investigational Product (IP). The severity of each adverse event (AE) and serious AE (SAE) was assessed by the investigator and graded based on a scale from Mild - mild symptoms to Severe AEs (non-serious or serious). A serious adverse event (SAE) is any AE which: * Resulted in death * Was life-threatening * Required inpatient hospitalization or prolongation of existing hospitalization * Resulted in persistent or significant disability/incapacity * Was a congenital anomaly/birth defect * Constituted an important medical event
| Participants | Placebo | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|
| Any TEAE | 72 | 106 | 96 |
| Any Drug-Related TEAE | 28 | 53 | 57 |
| Any Severe TEAE | 5 | 3 | 11 |
| Any Serious TEAE (SAE) | 3 | 6 | 4 |
| Any Drug-Related SAE | 0 | 3 | 1 |
| Any TEAE Leading to Drug Interruption | 11 | 16 | 31 |
| Any TEAE Leading to Drug Withdrawal | 3 | 5 | 12 |
| Any TEAE Leading to Death | 0 | 0 | 0 |
A treatment emergent adverse event (TEAE) is an AE with a start date on or after the date of the first dose of Investigational Product (IP). The severity of each adverse event (AE) and serious AE (SAE) was assessed by the investigator and graded based on a scale from Mild - mild symptoms to Severe AEs (non-serious or serious). A serious adverse event (SAE) is any AE which: * Resulted in death * Was life-threatening * Required inpatient hospitalization or prolongation of existing hospitalization * Resulted in persistent or significant disability/incapacity * Was a congenital anomaly/birth defect * Constituted an important medical event
| participants | Apremilast 20 mg (Pre-switch) | Apremilast 20 mg/30 mg (Post-switch) | Apremilast 30 mg BID |
|---|---|---|---|
| Any TEAE | 202 | 53 | 207 |
| Any Drug-related TEAE | 102 | 5 | 100 |
| Any Severe TEAE | 35 | 2 | 37 |
| Any Serious TEAE | 41 | 5 | 41 |
| Any Serious Drug-related TEAE | 6 | 1 | 6 |
| Any TEAE Leading to Drug Interruption | 47 | 4 | 65 |
| Any TEAE Leading to Drug Withdrawal | 24 | 3 | 30 |
| Any TEAE Leading to Death | 0 | 0 | 2 |
Collected over AEs are reported for the placebo-controlled phase from Week 0 to Week 16 for placebo participants who entered EE at Week 16 and up to Week 24 for all other participants. AEs are reported for the Apremilast Exposure Period from Week 0 to Week 260; overall median exposure to apremilast was 198 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Weeks 0-24: Placebo (Placebo-Controlled Phase) | — | 3/159 (1.9%) | 38/159 (23.9%) |
| Weeks 0-24: Apremilast 20 mg (Placebo- Controlled Phase) | — | 6/163 (3.7%) | 73/163 (44.8%) |
| Weeks 0-24: Apremilast 30 mg (Placebo- Controlled Phase) | — | 4/162 (2.5%) | 82/162 (50.6%) |
| APR Exposure Period Up to 5 Years: APR 20 mg | — | 41/234 (17.5%) | 154/234 (65.8%) |
| APR Exposure Period Up to 5 Years: APR 20mg/30 mg | — | 5/113 (4.4%) | 19/113 (16.8%) |
| APR Exposure Period Up to 5 Years: APR 30 mg | — | 41/234 (17.5%) | 166/234 (70.9%) |
| Event | Weeks 0-24: Placebo (Placebo-Controlled Phase) | Weeks 0-24: Apremilast 20 mg (Placebo- Controlled Phase) | Weeks 0-24: Apremilast 30 mg (Placebo- Controlled Phase) | APR Exposure Period Up to 5 Years: APR 20 mg | APR Exposure Period Up to 5 Years: APR 20mg/30 mg | APR Exposure Period Up to 5 Years: APR 30 mg |
|---|---|---|---|---|---|---|
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 1/159 | 0/163 | 0/162 | 3/234 | 0/113 | 0/234 |
| Psoriatic arthropathyMusculoskeletal and connective tissue disorders | 0/159 | 0/163 | 0/162 | 1/234 | 0/113 | 3/234 |
| DepressionPsychiatric disorders | 0/159 | 1/163 | 0/162 | 3/234 | 0/113 | 1/234 |
| Abscess soft tissueInfections and infestations | 0/159 | 0/163 | 0/162 | 0/234 | 1/113 | 0/234 |
| GastroenteritisInfections and infestations | 0/159 | 0/163 | 0/162 | 0/234 | 1/113 | 0/234 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/159 | 0/163 | 0/162 | 2/234 | 1/113 | 1/234 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/159 | 0/163 | 0/162 | 1/234 | 1/113 | 0/234 |
| Renal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/159 | 0/163 | 0/162 | 0/234 | 1/113 | 0/234 |
| Pelvic floor muscle weaknessReproductive system and breast disorders | 0/159 | 0/163 | 0/162 | 0/234 | 1/113 | 0/234 |
| Acute myocardial infarctionCardiac disorders | 0/159 | 0/163 | 0/162 | 2/234 | 0/113 | 0/234 |
| Event | Weeks 0-24: Placebo (Placebo-Controlled Phase) | Weeks 0-24: Apremilast 20 mg (Placebo- Controlled Phase) | Weeks 0-24: Apremilast 30 mg (Placebo- Controlled Phase) | APR Exposure Period Up to 5 Years: APR 20 mg | APR Exposure Period Up to 5 Years: APR 20mg/30 mg | APR Exposure Period Up to 5 Years: APR 30 mg |
|---|---|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 6/159 | 14/163 | 11/162 | 42/234 | 4/113 | 37/234 |
| DiarrhoeaGastrointestinal disorders | 8/159 | 18/163 | 25/162 | 33/234 | 0/113 | 40/234 |
| NauseaGastrointestinal disorders | 3/159 | 15/163 | 26/162 | 25/234 | 1/113 | 37/234 |
| BronchitisInfections and infestations | 0/159 | 5/163 | 6/162 | 19/234 | 1/113 | 30/234 |
| NasopharyngitisInfections and infestations | 6/159 | 9/163 | 9/162 | 28/234 | 4/113 | 30/234 |
| HeadacheNervous system disorders | 7/159 | 9/163 | 18/162 | 23/234 | 0/113 | 29/234 |
| Back painMusculoskeletal and connective tissue disorders | 0/159 | 5/163 | 3/162 | 22/234 | 0/113 | 14/234 |
| HypertensionVascular disorders | 7/159 | 4/163 | 5/162 | 21/234 | 4/113 | 22/234 |
| Urinary tract infectionInfections and infestations | 2/159 | 3/163 | 1/162 | 18/234 | 4/113 | 13/234 |
| SinusitisInfections and infestations | 4/159 | 4/163 | 3/162 | 17/234 | 1/113 | 15/234 |
Full analysis set consisting of all participants who were randomized as specified in the protocol. Four participants who were randomized in error and did not receive any dose of investigational product are excluded.
| Age, Continuous(years) | Placebo | Apremilast 20 mg | Apremilast 30 mg | Total |
|---|---|---|---|---|
| Mean | 51.2 ± 10.97 | 50.9 ± 11.82 | 50.5 ± 11.20 | 50.9 ± 11.32 |
| Sex: Female, Male(Participants) | Placebo | Apremilast 20 mg | Apremilast 30 mg | Total |
|---|---|---|---|---|
| Female | 85 | 95 | 95 | 275 |
| Male | 74 | 68 | 67 | 209 |
| Duration of Psoriatic Arthritis(years) | Placebo | Apremilast 20 mg | Apremilast 30 mg | Total |
|---|---|---|---|---|
| Mean | 7.76 ± 8.254 | 7.83 ± 8.621 | 6.82 ± 7.592 | 7.47 ± 8.163 |
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Data sharing details ↗ · www.amgen.com
Ran from Sep 2010 to primary completion in Jul 2012, 21 months.
Results were first posted in May 2014, 1 year 9 months after primary completion. A results delay was requested in May 2013.
Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 21 months is below that.
Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apremilast